Inflammation and the Heart
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Inflammation and the Heart|
- change in myocardial size and contractility measured by MRI [ Time Frame: before, and 6 months (24 weeks) after, starting disease modifying therapy ] [ Designated as safety issue: No ]
For RA patients, a baseline MRI study will be done before starting disease modifying therapy for RA. Starting therapy is decided by the patient's rheumatologist, so is standard of care. Six months (24 weeks) later a second MRI study will be done to see if treatment changes myocardial size and contractility.
For controls, baseline study only will be done.
Biospecimen Retention: Samples With DNA
|Study Start Date:||August 2012|
|Estimated Study Completion Date:||December 2017|
|Estimated Primary Completion Date:||December 2017 (Final data collection date for primary outcome measure)|
rheumatoid arthritis patients
People who have rheumatoid arthritis
people who do not have RA or other inflammatory disease
Aim 1: We want to study people with RA to see if we can detect very early changes in their heart muscle and compare these results to people who do not have RA.
Aim 2: We want to study people with RA, who have at least 4 swollen joints, before and 6 months after starting a disease modifying therapy to see if there are any changes in the heart muscle on treatment.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01589770
|United States, Tennessee|
|Nashville, Tennessee, United States, 37232|
|Principal Investigator:||Charles Michael Stein, MD||Vanderbilt University|